Radiopharm reports positive Phase 1 imaging data for RAD301 in pancreatic cancer patients

Reuters2026/09/09 11:04

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Radiopharm Theranostics reported positive Phase 1 imaging results for RAD301 in healthy volunteers, patients with pancreatic ductal adenocarcinoma.
Results have already been presented, showing a favorable safety profile, supportive biodistribution, meaningful tumor uptake across evaluable patients.
Low background signal in common metastatic sites supported clearer lesion detection, positioning RAD301 as a potential diagnostic, theranostic-enabling agent.
Data supported continued clinical development, with plans to advance RAD301 into a Phase 2 imaging trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609090700PRIMZONEFULLFEED1001261743) on September 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Radiopharm reports positive Phase 1 imaging data for RAD301 in pancreatic cancer patients

You may also like

Crypto prices